Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?
|
|
- Lionel Bryan
- 6 years ago
- Views:
Transcription
1 european urology supplements 5 (2006) available at journal homepage: Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications? M. Scott Lucia * Prostate Cancer Research Laboratories, Department of Pathology, University of Colorado at Denver and Health Science Center, Campus Box 8104, Biomedical Research Tower (RC1-North), Room 5128, Denver, CO, United States Article info Keywords: Biopsy Chemoprevention Detection 5a-reductase inhibitor Gleason grade Prostate cancer Abstract The 5a-reductase inhibitors (5-ARIs) have a number of effects on benign, hyperplastic, and malignant prostate epithelium. The extent of these effects appears to differ significantly among patients, and on average, appears less than that observed with luteinising hormone-releasing hormone (LHRH) agonist therapy. Indeed, the characteristic changes observed for hormonal therapy may not be so specific after all, if such changes can also be observed in men not receiving 5-ARIs or hormonal therapy. Although prostate specimens derived from men receiving a 5-ARI need to be interpreted with care, currently little evidence supports the original contention that use of a 5-ARI can result in significant misinterpretation of Gleason grade in those with prostate cancer. Data from the Prostate Cancer Prevention Trial (PCPT) strongly suggest that the reduction in prostate volume combined with changes in the performance of prostate-specific antigen (PSA) observed with 5-ARI treatment results in an excess detection of tumours, especially high-grade lesions, compared with untreated men. The effects of 5-ARIs on PSA appear to improve the predictive value of PSA as a diagnostic test for prostate cancer, possibly by differential suppression of PSA derived from cancerous and noncancerous tissue. New analyses, under development, are seeking to examine how this increased detection affects the reduction in risk of prostate cancer observed with 5-ARI therapy during the 7 yr of the PCPT. # 2006 Published by Elsevier B.V. on behalf of European Association of Urology. * Tel address: scott.lucia@uchsc.edu. 1. Introduction It has been understood for some time that treatment with 5a-reductase inhibitors (5-ARIs) has the ability to influence prostate cancer detection. Through inhibition of dihydrotestosterone (DHT) synthesis, 5-ARIs significantly reduce androgen drive to the prostate, which in its normal, hyperplastic, or cancerous state is androgen sensitive [1,2]. Androgens, particularly DHT, are recognised as the major regulator of prostate growth and differentiation. Interfering with the actions of androgen on the prostate results in glandular atrophy causing shrinkage of the prostate and reduction of prostate-specific antigen (PSA) synthesis [3]. The use of 5-ARIs, therefore, has the potential to alter /$ see front matter # 2006 Published by Elsevier B.V. on behalf of European Association of Urology. doi: /j.eursup
2 european urology supplements 5 (2006) prostate cancer detection in three ways: through effects on prostate histology that may alter the pathologist s view of a biopsy or radical prostatectomy specimen; through a decrease in the volume of the prostate, leading to alterations in suspicion of cancer on digital rectal examination (DRE) or through altered biopsy sampling; and through a reduction in serum PSA levels, resulting in an altered performance as a marker of suspicion for prostate cancer. Although postulated for years, more recent clinical data have produced a dramatic expansion of our knowledge of these effects and of their clinical implications. The completion of the Prostate Cancer Prevention Trial (PCPT) [4] and subsequent controversies over the incidence of tumours with high Gleason grades detected in the finasteride arm [5] have focussed considerable attention on these issues. The PCPT, sponsored by the National Cancer Institute and coordinated by the Southwest Oncology Group, evaluated the ability of finasteride to reduce the period-prevalence of prostate cancer, defined as the total number of prostate cancers diagnosed over a 7-yr period, in men taking the drug compared with placebo. Over 18,000 men were randomised to receive either finasteride (5 mg/d) or placebo and followed with annual examinations and PSA measurements. Biopsies of theprostatewereobtainedduringthestudydueto abnormal examination or PSA findings (for cause) and also at the end of the study regardless of examination or PSA findings. The study observed a 24.8% reduction in prostate cancer in the finasteride group compared with placebo [4].However,ahigher proportion of tumours with a Gleason score of 7 10 were detected in the finasteride group versus the placebo group (37.0% vs. 22.2% of graded tumours; p < 0.001), with the majority of this difference accounted for in the for-cause biopsies (Fig. 1). This raised the concern that alteration of the androgen balance through inhibition of 5a-reductase may promote the growth of more aggressive prostate tumours [4]. An important observation that pointed to an artifactual cause for this observation, rather than a true potentiation effect, was that the proportions of high-grade tumours in the two treatment arms did not diverge with time, a trend that would be expected if finasteride did promote the development of more aggressive tumours [6]. Furthermore, if finasteride did potentiate growth of high-grade cancer, then pathologic prognostic factors associated with tumour volume and extent would be expected to be greater in the high-grade tumours in the finasteride arm of the study compared with the Fig. 1 Gleason grade 7 10 tumours diagnosed in the Prostate Cancer Prevention Trial by timing of biopsy [4]. placebo arm. In contrast, preliminary results from the PCPT indicate that the tumours with Gleason scores 7 10 were less extensive in the finasteride arm compared with placebo for all of these features [7]. Other potential explanations for these observations therefore need to be examined. 2. Histopathologic effects of 5-ARIs For some time it has been known that treatment of benign prostatic hyperplasia (BPH) with the type-2 selective 5-ARI, finasteride, results in a reduction of prostate epithelial volume and an increase in the stromal-epithelial ratio of similar magnitude in the transitional and peripheral zones of the prostate [8]. Finasteride treatment of normal or hyperplastic prostate tissue results in atrophy and involution [9 14], smaller nuclei and nucleoli [11], increased apoptosis [12,15], decreased microvessel density [16,17], and no increase in cellular proliferation [15]. Although 5-ARIs are known to cause a number of histologic changes in normal and hyperplastic prostatic tissues, their direct effects on the morphology of prostate cancer are less clear. It is well established that luteinising hormone-releasing hormone (LHRH) agonist therapy has a profound impact on the morphology of cancer and the accuracy of Gleason grading, causing tumours of lower grade to artifactually appear high grade [18]. This has led to the consensus that Gleason grading should not be performed on tumours that have been hormonally treated [19]. However, substantive data of the effects of 5-ARIs on Gleason grading have not, until recently, become available.
3 754 european urology supplements 5 (2006) Two early studies examining the histologic effects of finasteride in men with prostate cancer provided differing results. Radical prostatectomy specimens reported alterations similar to, but less prominent than, those of LHRH agonists, with these changes occurring focally and only noticeable in low-grade tumours [9]. However, an examination of a subgroup of needle biopsy specimens from the Proscar Long-term Efficacy and Safety Study (PLESS) failed to demonstrate any effect of finasteride on tumour morphology [20]. More recent studies have again provided conflicting results. One study has examined the effects of the dual 5-ARI dutasteride. Among men with T1 or T2 prostate cancer scheduled to undergo radical prostatectomy who received dutasteride for 5 11 wk, tumour size was smaller, the stroma-gland ratio was increased, and the mean percentage of cancer epithelium with atrophic change was doubled compared with untreated men [21,22]. Yet, in another study of 45 men pretreated with finasteride for a minimum of 6 mo, the authors concluded that assignment of Gleason grade on biopsies or radical prostatectomy specimens was not compromised [23]. Furthermore, a recent study in 56 men receiving finasteride found that, although the characteristic changes of hormonal effects were observed in a higher proportion of men receiving a 5-ARI versus a group of matched controls, this difference was not statistically significant. This suggests that the characteristic changes observed are not specific for 5-ARI therapy [24]. Preliminary results from the PCPT are also in agreement with this last study [25]. Thus, although a consensus on the grading of cancer treated with 5-ARIs has not yet been reached, it can be said that 5-ARI therapy may be associated with changes in prostatic architecture, but such changes differ among subjects and may not always be readily separable from nontreatment-related changes. It was concluded that a grading bias as a result of 5-ARI therapy did not likely account for the Gleason observations in the PCPT, although the possibility remains that this may have confounded the grading in certain cases. Whether the effects differ significantly between dutasteride and finasteride remains to be elucidated. 3. Effects of 5-ARIs on prostate volume The effects of 5-ARIs in reducing prostate volume in men with BPH are well documented, with similar reductions in the transition and peripheral zones [8,26]. Finasteride treatment results in a reduction in total prostate volume of 18% over 4 yr [27], rising to 25% at 7 yr [4]. In a different patient population, treatment with dutasteride resulted in mean reductions of 26.0% at 24 mo and 27.3% at 48 mo [28]. The implication of these reductions for prostate cancer detection rests on the observation that tumours are easier to detect in smaller prostates [29]. Thus, in a prostate cancer prevention study using a 5-ARI, active treatment can enhance prostate cancer detection. This phenomenon likely led to a bias against the finasteride arm of the PCPT, with enhanced prostate cancer detection in men treated with finasteride. To what extent would this contribute to an excess detection of high-grade tumours in the finasteride arm of the PCPT? A recent retrospective review of transurethral ultrasound (TRUS)-guided prostate biopsies in 1475 men with prostate cancer with a PSA 10 ng/ml, of whom 369 underwent radical prostatectomy, has shown that a lower TRUSmeasured prostate volume was a significant predictor of a tumour of high Gleason grade at biopsy but not at radical prostatectomy. This demonstrates that smaller glands are associated with an increased detection of high-grade tumours presumably due to more thorough and comprehensive tumour sampling [30]. In the PCPT, a preliminary review of prostatectomy specimens indicates that the sensitivity of needle biopsy for detecting prostatectomyconfirmed high-grade cancer was almost 20% greater in the finasteride group than the placebo group (69.7% vs. 50.5%) [7]. Thus, the most likely explanation for the excess detection of tumours of high Gleason grade in the finasteride arm of the PCPT is the effect of finasteride on reducing prostate volume. It is also possible that effects on prostate histology and PSA, as discussed elsewhere in this article, could have biased prostate cancer detection in the finasteride arm. The induction of high-grade disease by finasteride also remains a possibility although this is considered significantly less likely by the PCPT investigators. 4. Effects of 5-ARIs on serum PSA Another important effect of 5-ARIs on prostate cancer detection is their known effect in reducing serum PSA levels over time. Early studies with finasteride demonstrated that it reduced serum PSA by a median of 50% over 12 mo [31], an observation that led to the introduction of the doubling rule to preserve the validity of the PSA value. Equivalent reductions in free and total PSA occur with 5-ARI treatment; an observation that has been made with both finasteride [32] and dutasteride [33]. Although it
4 european urology supplements 5 (2006) soon became clear that finasteride treatment beyond 1 yr resulted in further suppression of PSA in men with BPH, the sensitivity/specificity relationship for PSA in finasteride-treated men in one study was similar to that of placebo-treated men over 4 yr [34]. Comparable findings were also seen with the dual 5-ARI, dutasteride, which caused a median 59.5% decrease in PSA at 2 yr in men without a prostate cancer diagnosis [35]. One important limitation of these studies is that prostate biopsies were not mandatory either before or during the studies and, therefore, cancer detection by biopsy was conducted on a for-cause basis. It is very likely that a significant number of cases of prostate cancer went undetected and would therefore not have been part of the data set examining the sensitivity and specificity of PSA in men treated with a 5-ARI. It has also been recognised that for treatment periods of <12 mo, use of the generalised doubling rule could result in a higher rate of false-positive results (35% vs. 25%) for men receiving finasteride [36]. A subsequent study, which recruited men with biopsy-proven BPH or concomitant BPH/prostate cancer, demonstrated that, in the first 6 mo of treatment, more men with cancer receiving finasteride than placebo had a rise in PSA to >4 ng/ml and fewer had a decrease to <4 ng/ml, with the doubling rule applied [37]. This occurs because the median PSA in finasteride-treated men decreases steadily over the course of a year to reach a value of around 50% of baseline. Doubling in the first year can therefore significantly overestimate PSA. This phenomenon could potentially lead to an increased biopsy rate in finasteride-treated men in the first year of treatment. This was demonstrated in the PCPT where the biopsy rate was higher in the first year in finasteride- than placebo-treated men, despite being lower in every other year of the study, an observation that may have critical importance for the interpretation of the PCPT results [4]. Until the publication of data from the PCPT, the operating characteristics of PSA for detection of prostate cancer of different Gleason grades was not well understood. Derived from the placebo arm of the study, the area under the receiver operating characteristic curve (AUC) for PSA for any prostate cancer versus no prostate cancer was 0.678, a figure comparable with many other studies of the sensitivity and specificity of PSA (Fig. 2) [38]. However, the AUC for cancer of Gleason grade 7 versus no cancer or one with a Gleason grade of <7 was and that for cancer of Gleason grade 8 versus no cancer or one with a Gleason grade of <8 was These data demonstrate that PSA performs better for detecting Fig. 2 Receiver operating characteristic (ROC) curve of prostate-specific antigen (0 3.0 ng/ml) for the detection of prostate cancer of any grade and Gleason grades > 7 and > 8 from the Prostate Cancer Prevention Trial [38]. high-grade than low-grade cancer. Furthermore, when the AUC values were examined for the finasteride versus the placebo arm of the PCPT, the AUC values were higher in the finasteride arm for any prostate cancer, tumours with a Gleason score 7, and a Gleason score 8 [39]. Because, gram for gram, hyperplastic prostate tissue produces more PSA than prostate cancer tissue [40], and PSA may be a more accurate marker of hyperplasia than prostate cancer [41], it can be hypothesised that this increase in the AUC is related to suppression of PSA derived from normal or hyperplastic tissue to a greater extent than that from a prostate tumour. 5. Conclusions In conclusion, the 5-ARIs have a number of effects on benign, hyperplastic, and malignant prostate epithelium. The extent of these effects appears to differ significantly among patients, and on average, appears less than that observed with LHRH agonist therapy. Indeed the characteristic changes observed for hormonal therapy may not be so specific after all, if such changes can also be observed in men not receiving 5-ARIs or hormonal therapy. Although prostate specimens derived from men receiving a 5-ARI need to be interpreted with care, currently little evidence supports the original contention that 5-ARI use can result in significant misinterpretation of Gleason grade in those with prostate cancer.
5 756 european urology supplements 5 (2006) Data from the PCPT strongly suggest that the reduction in prostate volume combined with changes in the performance of PSA observed with 5-ARI treatment results in an excess detection of tumours, especially high-grade lesions, compared with untreated men. The effects of 5-ARIs on PSA appear to improve the predictive value of PSA as a diagnostic test for prostate cancer, possibly by differential suppression of PSA derived from cancerous and noncancerous tissue. New analyses, under development, are seeking to examine how this increased detection affects the reduction in risk of prostate cancer observed with 5-ARI therapy during the 7 yr of the PCPT. References [1] Isaacs JT. Antagonistic effect of androgens on prostatic cell death. Prostate 1984;5: [2] Kyprianou K, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50: [3] Rittmaster RS. 5 alpha-reductase inhibitors. J Androl 1997;18: [4] Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349: [5] Scardino PT. The prevention off prostate cancer the dilemma continues. N Engl J Med 2003;349: [6] Marberger M, Adolfsson J, Borkowski A, et al. The clinical implications of the prostate cancer prevention trial. BJU Int 2003;92: [7] Lucia MS, Darke A, Goodman P, et al. Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT). Abstract presented at the American Urological Association Annual Meeting, San Antonio, TX, May [8] Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53: [9] Civantos F, Watson RB, Pinto JE, Korman RB, Soloway MS. Finasteride effect on prostatic hyperplasia and prostate cancer: a comparative clinico-pathologic study of radical prostatectomies. J Urol Pathol 1997;6:1 14. [10] Montironi R, Valli M, Fabris G. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J Clin Pathol 1996;49: [11] Pomante R, Santinelli A, Muzzonigro G, Montironi R. Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride. Anal Quant Cytol Histol 1999;21:63 9. [12] Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81: [13] Saez C, Gonzalez-Baena AC, Japon MA, et al. Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 1998;37: [14] Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5. Prostate 2000;42: [15] Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factorbeta expression in benign prostatic hyperplasia. Prostate 2001;46: [16] Hochberg DA, Basillote JB, Armenakas NA, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002;167: [17] Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20 3. [18] Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996;14: [19] Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997;49: [20] Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? Urology 1999;53: [21] Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005;65: [22] Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172: [23] Carver BS, Kattan MW, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005;95: [24] Rubin MA, Allory Y, Molinie V, et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005;66: [25] Klein E, Tangen C, Goodman P, Lippman S, Thompson I. Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisted. Abstract presented at the American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, FL, February [26] Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60: [27] McConnell JD, Bruskewitz R, Walsh PC, et al. The effect of finasteride on the risk of acute urinary retention and the
6 european urology supplements 5 (2006) need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338: [28] Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46: [29] Remzi M, Djavan B, Wammack R, et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003;61: [30] Kulkarni G, Al-Azab R, Lockwood G, et al. Evidence for a biopsy-derived grade artifact among larger prostate glands: implications for the Prostate Cancer Prevention Trial. Abstract presented at the American Urological Association Annual Meeting, San Antonio, TX, May [31] Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 1993;20: [32] Espana F, Martinez M, Royo M, et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int 2002;90: [33] Andriole GL, Kirby R. Safety and tolerability of the dual 5areductase inhibitor dutasteride in the treatment of benign hyperplasia. Eur Urol 2003;44:82 8. [34] Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52: [35] Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175: [36] Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996;155:3 9. [37] Oesterling JE, Roy J, Agha A, et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Urology 1998;51: [38] Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: [39] Thompson IM, Chi C, Goodman P, et al. Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the Prostate Cancer Prevention Trial. Abstract presented at the American Urological Association Annual Meeting, Atlanta, GA, May [40] Magklara A, Scorilas A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000;56: [41] Bartsch G, Fitzpatrick J, Schalken J, et al. Consensus statement: role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004; 93:27 9.
Patient identifiers Date of request Accession/Laboratory number. CLINICAL STAGE (Note 3)
Prostate Core Needle Biopsy Histopathology Reporting Guide Part 1 - Clinical Information/Specimen Receipt Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationLooking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention
european urology 51 (2007) 27 33 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer
More informationHow Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationImpact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis
International Journal of Clinical Urology 2017; 1(1): 1-6 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j. ijcu.20170101.11 Review Article Impact of 5-Alpha Reductase Inhibitors Treatment
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationThe cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y
The cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y Record Status This is a critical abstract of an economic evaluation that
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationProstate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients
ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative
More informationThe Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial
european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary
More informationjournal of medicine The new england The Influence of Finasteride on the Development of Prostate Cancer abstract
The new england journal of medicine established in 1812 july 17, 2003 vol. 349 no. 3 The Influence of Finasteride on the Development of Prostate Cancer Ian M. Thompson, M.D., Phyllis J. Goodman, M.S.,
More informationAvailable for Public Disclosure Without Redaction
PROSCAR (finasteride 5 mg) Supplemental New Drug Application Prostate Cancer Prevention Trial Oncologic Drugs Advisory Committee Briefing Document Presented to ODAC on 01-December 2010 Available for Public
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationBPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD
BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College
More informationFinasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted. Mary W. Redman, Ph.D. 1. Catherine M. Tangen, Dr.
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted Modeling Approach Mary W. Redman, Ph.D. 1 Catherine M. Tangen, Dr. PH 1 Phyllis J. Goodman, MS 1 Howard Parnes, M.D.
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationDepartment of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
More informationPredicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationREVIEW The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia
(2008) 20, S19 S26 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The utility of serum prostatic-specific antigen in the management of men with benign
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationAlpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride
European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationDutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate Biopsy Increases Prostate Cancer Detection
european urology 53 (2008) 112 117 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Dutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate
More informationProstate Cancer Prevention with finasteride/proscar or dutasteride/avodart? Compiled by Charles (Chuck) Maack Prostate Cancer Advocate/Activist
Prostate Cancer Prevention with finasteride/proscar or dutasteride/avodart? Compiled by Charles (Chuck) Maack Prostate Cancer Advocate/Activist Disclaimer: Please recognize that I am not a Medical Doctor.
More informationSetting The setting was primary care. The economic study was conducted in the USA.
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationAlthough current American Cancer Society guidelines
ORIGINAL ARTICLE Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens Tamara L. Lotan, MD* and Jonathan I. Epstein, MD*w z Abstract: We have observed a group of
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationComparative Effect of Finasteride and Dutasteride on Chromogranin A Levels
Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels ALESSANDRO SCIARRA 1, STEFANO SALCICCIA 1, GIANLUCA NESI 2, SUSANNA CATTARINO 1, ANDREA ALFARONE 1, ALESSANDRO GENTILUCCI 1 and
More informationThe Hallmarks of BPH Progression and Risk Factors
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More information3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:
GU Evening Subspecialty Case Conference Rajal B. Shah, M.D. VP, Medical Director, Urologic Pathology Miraca Life Sciences, Irving, Texas Clinical Associate Professor of Pathology Baylor College of Medicine,
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationProstate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer
Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationEffect of Dutasteride Therapy on Doppler US Evaluation of Prostate: Preliminary Results 1
Genitourinary Imaging Elizabeth P. Ives, MD Leonard G. Gomella, MD Ethan J. Halpern, MD Published online 10.1148/radiol.2371041543 2005; 237:197 201 Abbreviations: BPH benign prostatic hyperplasia PSA
More informationASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES
ASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES I. E. PLEŞEA*, B. ZAHARIA*, S. D. ENACHE**, G. MITROI***, P. TOMESCU***, O. T. POP*, P. BADEA****, A. KOŻOKIĆ***** *Department
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationDoes normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationSignificance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
www.kjurology.org DOI:10.111/kju.010.51.1.81 Urological Oncology Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationTREATMENT EFFECTS IN THE PROSTATE INCLUDING THOSE ASSOCIATED WITH EMERGING FOCAL THERAPIES
TREATMENT EFFECTS IN THE PROSTATE INCLUDING THOSE ASSOCIATED WITH EMERGING FOCAL THERAPIES Andrew J. Evans MD PhD FRCPC Associate Professor and Staff Pathologist University Health Network Toronto. ON,
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More information(2015) : 85 (5) ISSN
Boniol, Mathieu and Autier, Philippe and Perrin, Paul and Boyle, Peter (2015) Variation of prostate-specific antigen value in men and risk of high-grade prostate vancer : analysis of the prostate, lung,
More informationFrequency and Outcome of Metaplasia in Needle Biopsies of Prostate and Its Relation With Clinical Findings
Urological Oncology Frequency and Outcome of Metaplasia in Needle Biopsies of Prostate and Its Relation With Clinical Findings Alireza Abdollahi, 1 Mohsen Ayati 2 Introduction: Metaplasia is a reversible
More informationEuropean Healthcare Innovation Leadership Network
MAY 2008 The Value Proposition of Medicines to Treat Benign Prostatic Hyperplasia: Introduction The following case study examines the evolution of Avodart, a drug manufactured by GSK that is currently
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationThe Benign Prostatic Hyperplasia and Its Aetiologies
The Benign Prostatic Hyperplasia and Its Aetiologies DR. MASOUD BASHEER O ALSHAMMARI DR. MOAZ HASSAN H ALHARBI DR. MOHAMMED ABDULLAH M ALHARTHI DR. ALMOTASEM BLLAH ALI Y ALHAZMI DR. AHMAD ENAD J ALENZI
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationOptimising the Medical Management of Benign Prostatic Hyperplasia
European Urology European Urology 45 (2004) 411 419 Review Optimising the Medical Management of Benign Prostatic Hyperplasia Michael Marberger a,*, Richard Harkaway b, Jean de la Rosette c a Department
More informationARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
More informationOutcomes Associated With the Use of Finasteride: An Evaluation of this Medication as a Chemoprotective Agent and its Efficacy
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-14-2010 Outcomes Associated With the Use of Finasteride: An Evaluation of this Medication
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationOutcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More information